Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2311-2320 Newer>

The Motley Fool August 24, 2005 Stephen D. Simpson	Sweet Air Around ResMed Growing awareness of breathing problems in sleep continues to fuel robust growth at the company. But with a fairly high valuation already in place, these shares aren't a recommended buy.
The Motley Fool August 24, 2005 Tarek Sultani	Panacos Gives HIV Reason to Panic Panacos' new anti-retroviral PA-457 has huge implications for the company's future. The stock price soared 46% Monday, closing at $10.30. While this surge may seem enormous, it's only the tip of the iceberg if this drug proves as successful as these trials indicate.
The Motley Fool August 23, 2005 W.D. Crotty	A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look?
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool August 22, 2005 Rich Smith	Possis' Possible Pitfalls The medical device maker reaffirms earlier guidance, but it's still not enough to justify the stock price.
Job Journal August 21, 2005 Julia Hollister	As America Ages, Pharmacists Flourish Demand for more druggists is swelling as baby boomers age. According to Department of Labor statistics, the outlook for employment is excellent and that trend is expected to continue for at least the next seven years.
The Motley Fool August 18, 2005 W.D. Crotty	Omnicare's Buying Binge The No. 1 provider of drug care for the elderly is growing rapidly -- and lining up new financing. Investors, take note.
The Motley Fool August 18, 2005 Stephen D. Simpson	Kensey Nash Needs to Kick It Up The med-tech company must deliver profit growth if it is to grow or maintain its valuation.
<Older 2311-2320 Newer> Return to current articles.